Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Pick Your #1 Kind Of Treat - 2Giant ‘toothed’ birds flew over Antarctica 40 million to 50 million years ago
- 3Mountain Trekking on a Tight spending plan: Tracking down the Right Bicycle
- 4Netanyahu leads meeting on West Bank riots, Katz defends axing administrative detention for Jews
- 5How Mars 'punches above its weight' to influence Earth's climate
- Find the Abilities Required for Advanced Advertising Position
- Why are malnutrition deaths soaring in America?
- Well known SUVs With Low Energy Utilization In 2024 vote
- Obamacare enrollment declines as US subsidies expire
- How to watch ‘The Traitors’ U.K. Season 4 premiere today from the U.S.
- Gaza amputees struggle to rebuild lives as the enclave faces shortages of prosthetic limbs
- France to build new nuclear aircraft carrier, Macron says
- Figure out how to Team up with Your Auto Crash Legal advisor for Best Outcomes
- Doritos and Cheetos debut 'NKD' options, without artificial colors or flavors
